CTVQ deployed at Mayo Clinic
Filed with ASX · · 3 pages · English
Summary by 6ix AI
4DMedical Ltd. announces the deployment of its CT:VQ™ technology at Mayo Clinic for ventilation and perfusion analysis, marking a significant endorsement of its capabilities. This deployment follows the successful rollout at five other leading U.S. Academic Medical Centers, demonstrating rapid adoption since FDA clearance. The initial agreement aims to integrate CT:VQ™ into clinical workflows, potentially expanding to full commercial terms. Mayo Clinic's choice to adopt this technology sends a strong signal about its clinical relevance in the healthcare market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from 4DMedical
- Update - S&P DJI March 2026 Rebalance of the All Ordinaries
- S&P DJI Announces March 2026 Quarterly Rebalance
- Appendix 4D and FY26 Half Year Report
- Response to ASX Query Letter
- University of Chicago Medicine adopts CTVQ
Later from 4DMedical
- CE Mark for CTVQ and $83M placement to fund EU expansion
- 4DMedical receives CE Mark for CT: VQ™, enabling commercial launch across the European Union
- Insignia Financial to be removed from the S&P/ASX 200 Index
- GSK contract, UK clearance for CTVQ, and ASX 200 inclusion
- Major publication validates CTVQ for lung surgery
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical